These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 16705696

  • 1. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A, Ochi M.
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M.
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.
    Cancer Res; 2010 Oct 01; 70(19):7610-9. PubMed ID: 20841471
    [Abstract] [Full Text] [Related]

  • 4. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.
    Clin Cancer Res; 2010 Jan 15; 16(2):530-40. PubMed ID: 20068094
    [Abstract] [Full Text] [Related]

  • 5. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V, Zhang W, Gidwani P, Kim M, Kolb EA.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY.
    Lung Cancer; 2008 Feb 15; 59(2):180-91. PubMed ID: 17900752
    [Abstract] [Full Text] [Related]

  • 7. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, Micksche M, Berger W.
    J Orthop Res; 2006 Jun 15; 24(6):1145-52. PubMed ID: 16602111
    [Abstract] [Full Text] [Related]

  • 8. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
    Horie N, Murata H, Nishigaki Y, Matsui T, Segawa H, Nogawa M, Yuasa T, Kimura S, Maekawa T, Fushiki S, Kubo T.
    Cancer Lett; 2006 Jul 08; 238(1):111-8. PubMed ID: 16112430
    [Abstract] [Full Text] [Related]

  • 9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 08; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 10. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K, Murata H, Koto K, Horie N, Matsui T, Nishigaki Y, Sakabe T, Takeshita H, Itoi M, Kimura S, Ashihara E, Maekawa T, Fushiki S, Kubo T.
    Anticancer Res; 2010 Jul 08; 30(7):2713-20. PubMed ID: 20683003
    [Abstract] [Full Text] [Related]

  • 11. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 12. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.
    Cancer Res; 2000 Nov 01; 60(21):6160-70. PubMed ID: 11085540
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
    Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M.
    Oncol Rep; 2005 Feb 01; 13(2):253-7. PubMed ID: 15643507
    [Abstract] [Full Text] [Related]

  • 14. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.
    Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.
    J Med Chem; 2007 Nov 15; 50(23):5579-88. PubMed ID: 17929792
    [Abstract] [Full Text] [Related]

  • 15. Suppression by incadronate of invasion and growth of A-375 human melanoma in mandible in nude mice.
    Kitagawa Y, Hiraga T, Yura Y, Yoneda T.
    Oncol Rep; 2005 Feb 15; 13(2):211-6. PubMed ID: 15643500
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
    Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM.
    Calcif Tissue Int; 2004 Jul 15; 75(1):71-7. PubMed ID: 15037971
    [Abstract] [Full Text] [Related]

  • 17. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
    Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N.
    BMC Cancer; 2007 Jan 12; 7():8. PubMed ID: 17222343
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway.
    Ishikawa C, Matsuda T, Okudaira T, Tomita M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T, Mori N.
    Br J Haematol; 2007 Feb 12; 136(3):424-32. PubMed ID: 17233845
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.
    Cancer Res; 2005 May 01; 65(9):3868-76. PubMed ID: 15867386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.